Form 4: Axsome Director Sells 25,000 Shares via Pre-Approved Plan

Axsome Therapeutics Director Mark Coleman sold 25,000 shares of common stock for a weighted average price of $161.11, completing a pre-approved 10b5-1 trading plan.

Summary

• Mark Coleman, a Director of Axsome Therapeutics, Inc. (AXSM), reported a sale of common stock.
• The transaction involved 25,000 shares of common stock.
• The shares were sold at a weighted average price of $161.11 per share, with individual sale prices ranging from $160.33 to $162.26.
• The total value of the shares sold is approximately $4,027,750 (25,000 shares * $161.11).
• The sale was executed on February 26, 2026.
• This transaction was made pursuant to a pre-approved Rule 10b5-1 trading plan, which has now been completed.
• Following the transaction, Mark Coleman directly beneficially owns 47,140 shares of common stock.
• Additionally, 403,856 shares are indirectly beneficially owned through an entity where the reporting person has voting and dispositive power.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale can sometimes be perceived negatively, the execution under a pre-approved 10b5-1 plan mitigates concerns, indicating a planned financial move rather than a reaction to new company-specific information.

Positives

• The transaction was conducted under a pre-approved Rule 10b5-1 plan, indicating a planned and scheduled sale rather than an immediate reaction to market conditions.
• The completion of the 10b5-1 plan provides transparency regarding the insider's trading activities.

Negatives

• A director selling a significant number of shares, even under a 10b5-1 plan, could be perceived by some investors as a lack of confidence, although this is often not the case with pre-scheduled plans.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, as its purpose is solely to report an insider transaction.

Industry Context

StockSavvy.ai notes that insider sales, particularly by directors, are common occurrences in the biotechnology and pharmaceutical sectors. While a sale of shares can sometimes raise questions, the execution under a Rule 10b5-1 plan is a standard practice for insiders to diversify holdings or manage personal finances without implying a negative outlook on the company's future. This type of planned transaction is generally viewed as less impactful than an unplanned, open-market sale.

Stakeholder Impact

• Shareholders: The sale of shares by a director could lead to minor, short-term sentiment shifts, but the pre-planned nature under a 10b5-1 plan typically limits significant impact. The director retains substantial direct and indirect ownership.

Key Dates

Recommendation

The sale of shares by a director, while notable, was conducted under a pre-approved 10b5-1 plan, which suggests a planned financial action rather than a reaction to new material information about Axsome Therapeutics. This type of transaction is generally considered a neutral event for the company's fundamentals and does not warrant a change in investment recommendation based solely on this filing. Investors should continue to hold and monitor broader company performance and industry trends.

Keywords

Axsome Therapeutics, AXSM, Form 4, Insider Trading, Mark Coleman, Director, Stock Sale, 10b5-1 Plan, Biotechnology, Pharmaceuticals